ARCH Venture Fund IX, L.P. - 27 Feb 2026 SCHEDULE 13D/A Report for Vir Biotechnology, Inc. Common Stock, $0.0001 par value (VIR)

Filing Manager
ARCH Venture Fund IX, L.P.
Reporting Manager
Robert Nelsen
Security
Vir Biotechnology, Inc. Common Stock, $0.0001 par value
Symbol
VIR
Shares outstanding
159,231,812 shares
Disclosed Ownership
13,534,704 shares
Ownership
8.5%
Form type
SCHEDULE 13D/A
Filing time
03 Mar 2026, 17:00:02 UTC
Date of event
27 Feb 2026
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ARCH Venture Fund IX, L.P. 8.1% 12,916,663 0 12,916,663 ARCH Venture Partners IX, L.P. its General Partner 0001666306
ARCH Venture Fund IX Overage, L.P. 8.1% 12,916,663 0 12,916,663 ARCH Venture Partners IX Overage, L.P. its General Partner 0001666307
ARCH Venture Partners IX, L.P. 8.1% 12,916,663 0 12,916,663 ARCH Venture Partners IX, LLC its General Partner 0001723173
ARCH Venture Partners IX Overage, L.P. 8.1% 12,916,663 0 12,916,663 ARCH Venture Partners IX, LLC its General Partner 0001723172
ARCH Venture Partners IX, LLC 8.1% 12,916,663 0 12,916,663 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director 0001723174
Robert Nelsen 8.5% 13,534,704 584,148 12,950,556 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Robert Nelsen 0001219042
Keith Crandell 8.3% 13,189,627 272,964 12,916,663 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Keith Crandell 0001219039
Clinton Bybee 8.1% 13,008,393 30,570 12,977,823 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Clinton Bybee 0001219043